The failure of most agents that hit a single target, including monoclonal antibodies such as Avastin that target the vascular endothelial growth factor (VEGF) and other antiangiogenic agents [15], eliciting quick drug resistance as well as giving rise to significant toxicity, clearly requires a new approach and a new conceptual framework for the treatment of cancers in general and GBM in particular [16, 17]. This evidence concerns the gene VEGFA and glioblastoma.